It is instructive to look at two ADEV examples as a practical skim through selected INS360 aspects. The hook journal article for first is 'Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma', 2017, PMID 28285914. The first reason for choosing this was that CCG-203971 was curated into GtoPdb as Ligand 6763 (show in Fig. ) and the earlier analogue CCG-1423 that 3971was optimised from is Ligand ID 6761. A second reason was that Professor Rick Neubig, as senior author on PMID 28285914, was a past Core Member of NC-IUPHAR and thus alerted GtoPdb to his earlier work that consequently picked up the entries above. Together with his colleague Scott Laursen the two of them have founded FibrosIX Inc as a start-up based on licensable assay technology assigned to The University of Michigan and Michigan State University. The company aims to develop novel anti-fibrotic agents which disrupt gene transcription (see this project plan poster). They have been awarded an SBIR grant from the National Cancer Institute of NIH to advance the development of CCG-257081 (n.b. do not overlook Google for the INS360 because this code name has a string of Google hits but no n2s in PubChem or PubMed). It should also be noted that FibrosIX Inc cannot be found as a patent assignee or PubMed (i.e. the Neubig patents are assigned to The Regents and Trustees of the University of Michigan). This is not to imply deliberate obfuscation but it emphasises the point made earlier that the academic origins, commercial affiliations and molecular outputs of ADEV teams can be difficult to track and connect up. Somewhat unusually the 2013 paper curated by GtoPdb actually precedes the 2016 WO patent (i.e. CCG-203971 was already prior art).